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Introduction
Hairy cell leukemia (HCL) was first described in the
medical literature at Ohio State University in 1958 by
Bouroncle et al.1 It is a rare, B-cell lymphoproliferative
malignancy, occurring predominantly in men and ac-
counting for 2% of all leukemias2.
HCL has a fairly indolent course, commonly present-
ing with pancytopenia, bone marrow infiltration,
splenomegaly, but mostly without evidence of signifi-
cant lymphadenopathy. Cytopenias are often severe,
particulary anemia and leukopenia, and usuallly lead to
the initiation of therapy, causing a high risk of infection.
Splenomegaly, which is usually massive, may trigger
the diagnostic workup3.
Several other uncommon complications have been
described in patients affected by hairy cell leukemia,
such as meningitis and nerve compression4, pleural ef-
fusion and ascites5 and immunological disorders6.
Among them, skeletal involvement is a clinically rele-
vant finding for the patient. Localized persisting pain is
the leading symptom in the majority of cases. Radiation
therapy (RT) has been shown to be effective7.
In this paper we present a patient with a destructive
bone lesion of HCL involving the left humeral head,
which was treated with RT. In addition, we briefly re-
view the available literature on this subject.
Case report
In 1996, a 54-year-old male carpenter was admitted
to the emergency department of our hospital because of
prolonged, severe fatigue. He had a clinical history of
antibiotic-resolved syphilis and ulcerative peptic dis-
ease. He reported weight loss of about 7 kg during the
last 60 days and a flu-like episode in the previous
month. Laboratory examinations were performed show-
ing the following results: cell blood count (CBC):
RBC: 2.23 x 1012/L; Hb 7.8 g/dL; MCV: 96 fl; MCH:
34.8 pg; WBC: 0.96 x 109/L; ANC: 0.24 x 109/L; lym-
phocytes: 620 x 109/L; monocytes: 110 x 109/L;
eosinophils: 20 x 109/L;  basophils: 10 x 109/L;
platelets: 20 x 109/L; ESR: 67 mm/h; total bilirubin: 1.4
mg/dL; indirect bilirubin: 1 mg/dL. 
Bone marrow aspiration failed; bone marrow biopsy
showed diffuse interstitial infiltration by CD20+ and
DBA44+ lymphocytes, with clear cytoplasm showing a
typical HCL pattern. Ultrasonography showed
splenomegaly with spleen diameters of 8 and 17 cm. No
enlarged lymph nodes were detected at any site. Treat-
ment with interferon alpha-2b was started at the stan-
dard dose of 2 x 106/m2 IU 3 times a week by subcuta-
neous injection for 12 months, resulting in normaliza-
tion of blood parameters lasting for 2 years. In May
1998, disease recurrence was documented and the inter-
feron alpha treatment was resumed until October 2000.
This resulted in normalization of CBC with marked re-
duction of bone marrow HCL involvement to less than
20%. A second relapse occurred in May 2001. At this
time, the patient was given cladribrine (2CdA) 0.09
mg/kg/day, but treatment was interrupted after 1 week
because of paroxysmal atrial flutter. In December 2002,
treatment with rituximab was started, with once-weekly
infusions at 375 mg/m2/week for 4 weeks, followed by
splenectomy a few months later. In December 2003 the
patient complained of left arm pain radiating to the ipsi-
lateral shoulder. Plain X-ray film showed a distrophic-
blastic area in the humeral head and metaphyseal re-
gion, without cortical discontinuity. CT and MRI
demonstrated a solid mass within the humeral head (5
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We report the case of a 63-year-old man with a clearly estab-
lished diagnosis of hairy cell leukemia, treated with multiple
lines of chemotherapy, who complained of localized pain in
the left humerus. Radiological findings showed a distrophic-
blastic area within the humeral head. Fine-needle biopsy con-
firmed the hypothesis of bone involvement of hairy cell
leukemia. The patient underwent radiotherapy at a dose of
25 Gy, obtaining a complete clinical response with resolution
of pain and a partial recovery of the normal radiological struc-
ture of the humerus after 2 months. In addition to the case re-
port, we present a short review of the literature focusing on
the role of radiotherapy in this subset of patients.
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cm diameter) and 2 satellite lacunar lesions located on
the humerus surgical neck (Figure 1). Bone scintigraphy
with 99Tc-MDP was positive only at that level. Fine-
needle biopsy was performed, with a histological find-
ing of hairy cells within the humerus. Examination of
the biopsy specimen showed diffuse infiltration of tra-
becular bone by monomorphic neoplastic elements with
oval or indented nuclei and abundant pale cytoplasm.
These cells were strongly immunoreactive for CD20
and tartrate-resistant acid phosphatase and showed
weak-moderate positivity for CD76 (DBA44) (Figure
2). After performing a complete restaging procedure,
we observed no other evidence of disease at the time of
bone involvement.
Since the bone pain was worsening, with impaired left
arm function, the patient was referred to our radiation
oncology department for clinical evaluation. After re-
view of the radiological imaging, the whole humerus
was treated with 25 Gy in 10 fractions using parallel op-
posed fields with 6-MV photons. Substantial pain relief
was obtained a few days after the start of RT, and a com-
plete clinical response was observed by the end of the
whole treatment. Plain X-ray after 2 months showed par-
tial recovery of the bone structure at the involved site.
Discussion
Skeletal involvement during HCL is an uncommon,
but well described event. The reported incidence ranges
from 0% to 13% in different series8-10. Most patients
have a previous history of HCL when developing bone
lesions; in rare cases bone lesions are the initial disease
manifestation leading to the diagnosis11. Nevertheless, a
presentation as localized skeletal involvement without
abnormal peripheral blood counts, splenomegaly or
bone marrow infiltration has been described12.
Most of these lesions develop in the axial skeleton or
in the proximal part of long bones13. Commonly in-
volved sites are the femoral head and neck, vertebral
column, pelvis, skull, tibia, humeral head and femoral
diaphysis7. Localized, prolonged pain is the most
prominent clinical feature in almost all cases. More
rarely there are multiple painful sites, sometimes asso-
ciated with arthralgia and joint effusion14.
Local skeletal lesions can be successfully treated with
radiotherapy, achieving rapid and substantial pain re-
lief15. Several fractionation schedules and total doses
have been reported in published papers.  The first report
is by Rhyner et al.16, who described 3 cases of bone
metastases of HCL. Two were irradiated, with a dose of
60 Gy in one case and of 8 Gy in a single fraction in the
other. In both cases there was resolution of hip pain.
One of the largest series has been described by Lem-
bersky et al.8 These authors reviewed the records of 267
HCL patients at the University of Chicago and identi-
fied 8 cases of skeletal complications. The latter pa-
tients were treated with radiotherapy at doses ranging
from 15 Gy to 30 Gy. In all cases there was symptom
improvement. In this series, bone lesions were clearly
associated with a large tumor burden, with all patients
examined having hypercellular marrow with at least
90% of the hematopoietic elements being hairy cells. In
the paper by Quesada et al.15, 4 patients with bone in-
volvement are described. Two of them were treated with
radiotherapy (20-25 Gy), with marked pain relief and a
complete radiological response in one case. No relation-
ship between skeletal involvement and tumor burden
was found by the authors.
The work by Demanes et al. reports 2 cases of HCL
with bone lesions11. One of these patients was treated
with 60 Gy in 30 fractions. Interestingly, the patient de-
veloped aseptic necrosis of the femoral head. The au-
thors conclude that radiation therapy in moderate doses
(approximately 5000 rad in 5 weeks) is beneficial in pa-
tients with symptomatic or strategically located bone le-
sions.
From this short overview of the literature it seems
clear that there is no general agreement on the best radi-
ation treatment for skeletal localization of HCL in terms
of dose and fractionation. If we consider the matter
from a radiobiological point of view, low doses are
probably sufficient to obtain complete disease control17.
Leukemic clones of B-cell origin like HCL are extreme-
ly radiosensitive, with a surviving fraction after 2 Gy
(SF2) in vitro of approximately 0.2-0.3. Taking into ac-
count these SF2 values, a dose of 20-25 Gy given with
conventional fractionation is theoretically sufficient to
reduce a clone of 109 cells to 1. In treating our patient,
Figure 1 - Circumscribed replacement of the normal bone marrow by
patchy areas of low signal intensity on both T1- and T2-weighted MRI
images within left humeral head.
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we chose a slightly more aggressive fractionation
schedule because of the rapid disease progression with
extensive humeral involvement and difficult pain con-
trol. Low toxicity is expected with this kind of treat-
ment, allowing fractionation to be adapted to the pa-
tient’s characteristics. In conclusion, since skeletal in-
volvement seems not to affect prognosis and since sys-
temic disease can be well controlled with drugs (inter-
feron alpha, pentostatin, cladribine), it is worth treating
this kind of patient with eradicating intent (in terms of
adequate dose), but with attention to the issue of normal
tissue preservation.
Figure 2 - Hematoxylin and eosin-stained section (original magnification x400) showing infiltration of trabecular bone by neoplastic cells with oval-in-
dented nuclei and abundant cytoplasm. A) Immunohistochemistry showed positivity for B) CD20, C) CD76 and D) tartrate-resistant acid phosphatase
(original magnification x400).
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